Risk stratification and medical therapy of pulmonary arterial hypertension

Nazzareno Galiè, Richard N. Channick, Robert Frantz, Ekkehard Grünig, Zhi Cheng Jing, Olga Moiseeva, Ioana R. Preston, Tomas Pulido, Zeenat Safdar, Yuichi Tamura, Vallerie V. McLaughlin

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.

Original languageEnglish (US)
JournalThe European respiratory journal
Volume53
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pulmonary Hypertension
Therapeutics
Right Ventricular Function
Lung Transplantation
Endothelins
Epoprostenol
Nitric Oxide
Hemodynamics
Exercise
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Galiè, N., Channick, R. N., Frantz, R., Grünig, E., Jing, Z. C., Moiseeva, O., ... McLaughlin, V. V. (2019). Risk stratification and medical therapy of pulmonary arterial hypertension. The European respiratory journal, 53(1). https://doi.org/10.1183/13993003.01889-2018

Risk stratification and medical therapy of pulmonary arterial hypertension. / Galiè, Nazzareno; Channick, Richard N.; Frantz, Robert; Grünig, Ekkehard; Jing, Zhi Cheng; Moiseeva, Olga; Preston, Ioana R.; Pulido, Tomas; Safdar, Zeenat; Tamura, Yuichi; McLaughlin, Vallerie V.

In: The European respiratory journal, Vol. 53, No. 1, 01.01.2019.

Research output: Contribution to journalArticle

Galiè, N, Channick, RN, Frantz, R, Grünig, E, Jing, ZC, Moiseeva, O, Preston, IR, Pulido, T, Safdar, Z, Tamura, Y & McLaughlin, VV 2019, 'Risk stratification and medical therapy of pulmonary arterial hypertension', The European respiratory journal, vol. 53, no. 1. https://doi.org/10.1183/13993003.01889-2018
Galiè, Nazzareno ; Channick, Richard N. ; Frantz, Robert ; Grünig, Ekkehard ; Jing, Zhi Cheng ; Moiseeva, Olga ; Preston, Ioana R. ; Pulido, Tomas ; Safdar, Zeenat ; Tamura, Yuichi ; McLaughlin, Vallerie V. / Risk stratification and medical therapy of pulmonary arterial hypertension. In: The European respiratory journal. 2019 ; Vol. 53, No. 1.
@article{97ea6c85bcff4310b46ff4a283c23ee3,
title = "Risk stratification and medical therapy of pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.",
author = "Nazzareno Gali{\`e} and Channick, {Richard N.} and Robert Frantz and Ekkehard Gr{\"u}nig and Jing, {Zhi Cheng} and Olga Moiseeva and Preston, {Ioana R.} and Tomas Pulido and Zeenat Safdar and Yuichi Tamura and McLaughlin, {Vallerie V.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1183/13993003.01889-2018",
language = "English (US)",
volume = "53",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Risk stratification and medical therapy of pulmonary arterial hypertension

AU - Galiè, Nazzareno

AU - Channick, Richard N.

AU - Frantz, Robert

AU - Grünig, Ekkehard

AU - Jing, Zhi Cheng

AU - Moiseeva, Olga

AU - Preston, Ioana R.

AU - Pulido, Tomas

AU - Safdar, Zeenat

AU - Tamura, Yuichi

AU - McLaughlin, Vallerie V.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.

AB - Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.

UR - http://www.scopus.com/inward/record.url?scp=85060512382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060512382&partnerID=8YFLogxK

U2 - 10.1183/13993003.01889-2018

DO - 10.1183/13993003.01889-2018

M3 - Article

C2 - 30545971

AN - SCOPUS:85060512382

VL - 53

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 1

ER -